Amneal launches lyvispah® (baclofen) for spasticity related to multiple sclerosis and other spinal cord disorders

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the commercial launch of lyvispah®, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the u.s. food and drug administration (“fda”) for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders. lyvispah is bioequivalent to oral baclofen tablets and provides flexible, customized dosing with 5mg, 10mg and 20mg single-dose
AMRX Ratings Summary
AMRX Quant Ranking